Pharmacokinetics/Dynamics of Corticosteroids

  • William J. Jusko


The corticosteroids are important immunosuppressive and antiinflammatory agents used in treatment of numerous pathophysiologic conditions. Their therapeutic use is complicated by numerous adverse effects when used chronically and there is considerable empiricism in selecting appropriate doses.


Cortisol Concentration Receptor Occupancy Pharmacodynamic Model Tyrosine Aminotransferase Cytosolic Receptor 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    W. J. Jusko. Corticosteroid pharmacodynamics: Models for a broad array of receptor-mediated pharmacologic effects. J. Clin. Pharmacol. 30:303–310 (1990).PubMedCrossRefGoogle Scholar
  2. 2.
    A-N. Kong, E. A. Ludwig, R. L. Slaughter, P. M. DiStefano, J. DeMasi, E. Middleton Jr., and W. J. Jusko. Pharmacokinetics and pharmacodynamic modeling of direct suppression effects of methylprednisolone on serum cortisol and blood histamine in human subjects. Clin. Pharmacol. Ther. 46:616–628 (1989).PubMedCrossRefGoogle Scholar
  3. 3.
    J. A. Wald and W. J. Jusko. Two-compartment basophil cell trafficking model for methylprednisolone pharmacodynamics. Pharmaceut. Res. 7:S–219 (1990).Google Scholar
  4. 4.
    W. J. Jusko, W. R. Slaunwhite, and T. Aceto Jr. Partial pharmacodynamic model for the circadian-episodic secretion of cortisol in man. J. Clin. Endocrinol. Metab. 40:278–289 (1975).PubMedCrossRefGoogle Scholar
  5. 5.
    W. G. Reiss, R. L. Slaughter, E. A. Ludwig, E. Middleton, and W. J. Jusko. Steroid dose sparing: Pharmacodynamic responses to single versus divided doses of methylprednisolone in man. J. Allergy Clin. Immun. 85:1058–1066 (1990).PubMedCrossRefGoogle Scholar
  6. 6.
    T. Dunn, E. Ludwig, R. Slaughter, D. Camara, and W. J. Jusko. Comparative pharmacokinetics and pharmacodynamics of methylprednisolone in obese and non-obese men. Clin. Pharmacol Ther. 47:181 (1990).Google Scholar
  7. 7.
    F. D. Boudinot, R. D’Ambrosio, and W. J. Jusko. Receptor-mediated pharmacodynamics of prednisolone in the rat. J. Pharmacokin. Biopharm. 14:469–493 (1986).CrossRefGoogle Scholar
  8. 8.
    A. I. Nichols, F. D. Boudinot, and W. J. Jusko. Second generation model for prednisolone pharmacodynamics in the rat. J. Pharmacokin. Biopharm. 17:209–227 (1989).CrossRefGoogle Scholar
  9. 9.
    A. I. Nichols, R. D’Ambrosio, and W. J. Jusko. Pharmacokinetics and pharmacodynamics of prednisolone in obese rats. J. Pharmacol. Exp. Ther. 250:963–970 (1989).PubMedGoogle Scholar
  10. 10.
    A. I. Nichols and W. J. Jusko. Receptor mediated prednisolone pharmacodynamics in rats: Model verification using a dose-sparing regimen. J. Pharmacokin. Biopharm. 18:189–208 (1990).CrossRefGoogle Scholar
  11. 11.
    D. B. Haughey and W. J. Jusko. Receptor-mediated pharmacodynamics of methylprednisolone in the rat. Pharmaceut. Res. 7:S–240 (1990).Google Scholar

Copyright information

© Springer Science+Business Media New York 1991

Authors and Affiliations

  • William J. Jusko
    • 1
  1. 1.Department of PharmaceuticsState University of New York at BuffaloUSA

Personalised recommendations